本文已被:浏览 1101次 下载 300次 |
码上扫一扫! |
|
安罗替尼相关甲状腺功能异常:一项真实世界观察研究 |
李芳1, 张秀萍1, 李智勇1, 刘天舒1,2, 周宇红2, 王志明1,2
|
1.复旦大学附属中山医院厦门医院肿瘤内科, 厦门 361015;2.复旦大学附属中山医院肿瘤内科, 上海 200032
|
|
摘要: |
目的 探讨真实世界应用安罗替尼的恶性肿瘤患者合并甲状腺功能异常的情况。方法 收集2019年7月至2020年7月复旦大学附属中山医院及厦门医院收治的应用安罗替尼超过2个疗程的146例恶性肿瘤患者资料,分析患者甲状腺功能。结果 146例患者中,基线甲状腺功能正常者110例,随访过程中新出现甲状腺功能异常的比例为38.2%(42/110),其中甲状腺功能减退症占19.1%(21/110),亚临床甲状腺功能减退症占14.5%(16/110),甲状腺功能亢进症占3.4%(5/110),均为1/2级。上述异常一般出现在起始安罗替尼治疗的6个月内(92.6%),无患者因甲状腺功能异常而停用安罗替尼。结论 真实世界应用安罗替尼患者甲状腺功能异常发生率为38.2%,以甲状腺功能减退症为主,一般出现在安罗替尼治疗后的6个月内出现,不影响抗肿瘤治疗。 |
关键词: 靶向治疗 安罗替尼 甲状腺功能 |
DOI:10.12025/j.issn.1008-6358.2022.20211992 |
分类号:R73 |
基金项目:复旦大学附属中山医院厦门医院孵化课题(2019ZSXMYS10). |
|
Anlotinib associated thyroid dysfunction: a real-world study |
LI Fang1, ZHANG Xiu-ping1, LI Zhi-yong1, LIU Tian-shu1,2, ZHOU Yu-hong2, WANG Zhi-ming1,2
|
1.Department of Medical Oncology, Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen 361015, Fujian, China;2.Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China
|
Abstract: |
Objective To explore the incidence of thyroid dysfuction in anlotinib treated malignant tumor patients in real world. Methods The data of 146 patients with malignant tumors treated with arotinib for more than two courses in Xiamen Branch, Zhongshan Hospital, Fudan University from July 2019 to July 2020 were collected, and the thyroid functions were analyzed. Results Among 146 patients, 110 patients had normal thyroid function. The incidence rate of newly-diagnosed thyroid dysfunction was 38.2% (42/110) during follow-up, including 19.1%(21/110) with hypothyroidism, 14.5%(16/110) with subclinical hypothyroidism, and 3.4%(5/110) wih hyperthyroidism, they were all Grade 1/2. 92.6% of these abnormalities occurred within 6 months after the initial treatment of anlotinib. No patients altered antineoplastic therapy because of hypothyroidism. Conclusion Hypothyroidism is common in the real-world application of anlotinib, but the occurrence of hypothyroidism does not affect antineoplastic therapy. |
Key words: targeted therapy anlotinib thyroid function |